There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Olema Pharmaceuticals (OLMA – Research Report), 2seventy bio (TSVT – Research Report) and Marinus (MRNS – Research Report) with bullish sentiments.
Olema Pharmaceuticals (OLMA)
H.C. Wainwright analyst Emily Bodnar maintained a Buy rating on Olema Pharmaceuticals today and set a price target of $28.00. The company’s shares closed last Wednesday at $10.85.
According to TipRanks.com, Bodnar is a 4-star analyst with an average return of
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Olema Pharmaceuticals with a $26.00 average price target, which is a 137.2% upside from current levels. In a report issued on May 1, Citi also maintained a Buy rating on the stock with a $20.00 price target.
See Insiders’ Hot Stocks on TipRanks >>
2seventy bio (TSVT)
In a report released yesterday, John Newman from Canaccord Genuity maintained a Buy rating on 2seventy bio, with a price target of $11.00. The company’s shares closed last Wednesday at $4.48.
According to TipRanks.com, Newman is a 4-star analyst with an average return of
2seventy bio has an analyst consensus of Moderate Buy, with a price target consensus of $11.50, which is a 134.2% upside from current levels. In a report issued on April 26, Leerink Partners also maintained a Buy rating on the stock.
Marinus (MRNS)
Ladenburg Thalmann & Co. analyst Michael Higgins maintained a Buy rating on Marinus today and set a price target of $4.00. The company’s shares closed last Wednesday at $1.43, close to its 52-week low of $1.11.
According to TipRanks.com, Higgins is a 3-star analyst with an average return of
Currently, the analyst consensus on Marinus is a Moderate Buy with an average price target of $8.56, which is a 455.8% upside from current levels. In a report released yesterday, JMP Securities also reiterated a Buy rating on the stock with a $10.00 price target.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Read More on OLMA:
- 3 Best Stocks to Buy Now, 5/9/2024, According to Top Analysts
- Olema Oncology Reports First Quarter 2024 Financial Results and Provides Corporate Update
- Olema Oncology Announces New Clinical Data for Palazestrant in Combination with Ribociclib to be Presented at the 2024 ESMO Breast Cancer Annual Congress
- Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- Citi opens ‘positive catalyst watch’ on Olema Oncology into data
